"I am driven by finding practical solutions to challenging chemical problems that could eventually make a difference in patient’s lives."
I joined the small molecule process chemistry group in 2010 after a postdoctoral stint with Prof. Stephen Buchwald at MIT. My current role includes leading team efforts developing efficient and robust chemical processes to supply the active pharmaceutical ingredient (API) for clinical studies and building internal technology platforms in the area of high-throughput experimentation (HTE), transition-metal catalysis, and continuous flow chemistry.
Org. Lett. 2017, 19, 4806–4809.
As a process chemist, I strive to develop highly efficient and robust chemical/biochemical processes to support drug development needs on the active pharmaceutical ingredient (API), including supplies for clinical studies. In addition, I am motivated to build/develop state-of-the-art technology platforms such as high-throughput experimentation (HTE) and continuous flow chemistry to maximize our efficiency tackling challenging problems.